Abstract 589P
Background
Circulating tumor DNA (ctDNA) based molecular residual disease (MRD) detection has been shown to predict prognosis and guide individualized management of colorectal cancer (CRC). The landmark point is usually set at 4-12 weeks post resection in consideration of the disturbance to cell-free DNA (cfDNA) by surgery. This study aimed to evaluate the feasibility of moving the landmark point to 1-week post resection.
Methods
The study prospectively and consecutively enrolled stage I-IV CRC patients who received R0 resection. Blood samples at baseline, post-operative day (POD) 7, POD30 and subsequent every 3-6 months surveillance were collected. The MRD status of all the samples were evaluated by the Burning Rock Patient-specific pROgnostic and Potential tHErapeutic marker Tracking (brPROPHETTM) approach. The cfDNA level, mean tumor mutant (MTM), positive predictive value (PPV) and negative predictive value (NPV) were compared between POD7 and POD30.
Results
In total, 164 eligible patients were enrolled. The median follow-up duration was 311 days (95% CI, 296-351) up to date. The brPROPHET displayed a high sensitivity of 95.1% (155/163) for detecting ctDNA preoperatively, with 88.5%, 96.1%, 96.2%, 100% in stage I to IV, respectively. Post-resection ctDNA positive rates were decreased to 15.2% (25/164) at POD7 and 12.8% (21/164) at POD30. The cfDNA levels of POD7 were significantly higher than those of baseline and POD30 (P<0.001). However, the MTMs were similar between POD7 and POD30 (P = 0.55). The accordance between POD7 and POD30 was 91.5% (150/164). For 6-month recurrence, the PPV was 13.6% vs 15.8% for POD7 and POD30, respectively, with NPV of 100% vs 98.2%. Of the 25 ctDNA positive patients at POD7, 9 turned negative at POD30 and had significantly lower ctDNA levels at POD7 than those who didn’t (P<0.001). Patients with decreased ctDNA from POD7 to POD30 had a higher ctDNA clearance rate during surveillance than those without decreased ctDNA (100% vs 30%, P = 0.02).
Conclusions
The performance of ctDNA detection in POD7 and POD30 was similar. Shift of the landmark time to 1-week post resection may provide an easier way to evaluate MRD status for prognostic stratification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
622P - Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild type metastatic colorectal cancer (mCRC) treated with first-line (1L) panitumumab (PAN) plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE
Presenter: Marcel Reiser
Session: Poster session 10
623P - VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer
Presenter: Yijiao Chen
Session: Poster session 10
624P - Tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated /MSS metastatic colorectal cancer
Presenter: Meng Qiu
Session: Poster session 10
625P - Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study
Presenter: Claire Gallois
Session: Poster session 10
626P - Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations
Presenter: Francisco Javier Ros Montana
Session: Poster session 10